Drug intelligence / Profile preview

CUG-288

Development stage: Unknown
Lead developer: Cugene
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

CUG-288 is a fusion protein drug developed by Cugene. It functions as an interleukin-2 (IL-2) replacement and acts as a stimulant of T lymphocytes. The drug is designed to preferentially induce proliferation, expansion, and activation of tumor-infiltrating lymphocytes (TILs), thereby enhancing anti-tumor immune responses. Its primary therapeutic area is oncology, specifically for the treatment of solid tumors. As an IL-2 stimulant, it aims to harness the immune system's ability to target and destroy cancer cells by modulating the activity of T cells[1][2].

Other names: TILKine-2TILKine2TILKine 2

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on CUG-288.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUG-288.

Explore the full profile